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Vascular-targeted carriers (VTCs) are often designed as leukocyte mimics, conjugated with ligands that target 
leukocyte adhesion molecules (LAMs) to facilitate specific adhesion to diseased endothelium. VTCs must 
adhere in regions with dynamic blood flow, frequently requiring multiple ligand-receptor (LR) pairs to provide 
particle adhesion and high disease specificity. To study LR kinetics under flow, multiple research groups have 
used protein-coated plates to study the adhesion and rolling of dual-targeted particles in vitro.1-4 While important 
knowledge is contributed by these studies, they lack the complexity of a diseased physiologic endothelium, as 
spatiotemporal LAM expression varies widely. Despite decades of research with the ambition of mimicking 
leukocytes, the specificity of multiple LAM-targeted VTCs remains poorly understood, especially in physiological 
environments. More specifically, there is a lack of mechanistic understanding of how multiple ligands interact 
with biologically complex endothelial surfaces under dynamic in vivo environments.  
 
We used cutting-edge intravital microscopy to investigate particle 
binding to an inflamed mesentery with a series of particles with 
well-controlled ligand properties. For all intravital experiments, we 
characterized the number of rolling and firmly bound particles, as 
well as the rolling velocity of each. We found that the total 
number of sites of a single ligand can drive particle adhesion to 
the endothelium, however, combining ligands that target multiple 
LR pairs provides a more than additive result. Combining sLeA 
and anti-ICAM, LAM ligands targeting selectin and β2 integrin 
mediated paths of adhesion respectively, resulted in ~3-7-fold 
increase of adherent particles at the mesentery endothelium over 
single-ligand particles. At a constant total ligand density, a 
particle with a ratio of 75% sLeA: 25% anti-ICAM resulted in more 
than 3-fold increase over all over other ligand ratios tested in our 
in vivo model (Figure 1). In vitro parallel plate flow chamber 
experiments using human whole blood agree with these results. 
Particles with a ratio of 75% sLeA: 25% anti-ICAM produced ~6-
fold more bound particles over all other particle types at a time 
point of maximal ICAM expression on the endothelial cells (ECs). 
Taken together, we conclude the best dual-ligand design of a particle is heavily dependent on the surface 
expression of the ECs. Interestingly, particle adhesion is most efficient when more ligand is present for the 
lesser-expressed receptor. The novel use of intravital microscopy to investigate the effect of dual targeting 
ligands establishes the importance of LR-kinetics in ligand design for future therapeutics.  
This work is specifically relevant to Nanotechnology in Medicine because it dives deeply into the mechanistic 
understanding of the molecular interactions between ligands on particles and receptors on cells. Our work 
propels the field forward by establishing the importance of particle ligand ratios based on EC receptor patterns.  
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Figure 1 – Particle adhesion to inflamed 
mesentery endothelium as a function of 
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